Wave Neuroscience

Wave Neuroscience operates at the intersection of digital therapeutics, neurodiagnostics, and neuromodulation. Its differentiation is the combination of Braincare™ software, Neurodynamics™ assessment, advanced neuroimaging, and personalized MeRT® treatment protocols rather than a standalone stimulation device or general-purpose mental-health application. The 2026 FDA clearance for MeRT in PTSD gives the company a concrete clinical indication and may improve adoption prospects with providers seeking regulated treatment options. Its partnership with the Texas A&M Health Institute of Biosciences and Technology adds an academic and research-oriented dimension to the platform. The company’s positioning is particularly relevant to clinics that want patient-specific treatment protocols informed by objective brain data. The company remains private, with one disclosed funding round and no public valuation.

Wave Neuroscience shows a trajectory from early brain-health development toward a more regulated clinical platform. Founded in 2019, the company acquired Newport Brain Research Laboratory on Dec 6, 2019 and NeoSync on Feb 26, 2020, suggesting an early effort to build capabilities across research, diagnostics, and neuromodulation. Regulatory progress became a clear inflection point in 2024, when MeRT received FDA Breakthrough Device Designation for PTSD on Dec 3, 2024. The next major step came on Jun 11, 2026, when the MeRT System received FDA clearance for clinical treatment of PTSD. That milestone changes the company’s development profile from primarily technology and treatment innovation toward commercialization of a cleared indication. The 2026 partnership with the Texas A&M Health Institute of Biosciences and Technology supports continued research, while August 2026 coverage indicates growing attention from the broader neuromodulation market. Employee data places the organization in the 51–100 employee range, but no hiring trend, revenue, or deployment metrics are disclosed.